Gland Pharma Surges 15% to New 52-Week High Following Strong Q4 Earnings

Gland Pharma Shares Hit 52-Week High After Strong Q4 Earnings

Shares of Gland Pharma reached their 52-week high in afternoon trade on Monday following a robust set of March quarter earnings. The stock surged 14.67% to Rs 2,142.30 on the NSE, making it one of the top gainers of the session.

The company's stock had previously touched its 52-week low of Rs 1,452.20 on May 19, 2025. Gland Pharma's performance was marked by a significant jump in consolidated profit after tax, which rose by 96.56% to Rs 366.67 crore in Q4FY26, compared with Rs 186.54 crore in the corresponding quarter last year.

Earnings Highlights

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

The revenue from operations increased by 22.3% year-on-year to Rs 1,742.79 crore in the March quarter, against Rs 1,424.90 crore in the year-ago period. The company attributed this growth to capacity expansion and the ramp-up of new products. Additionally, contract and pricing renegotiations, cost optimization measures, and operating leverage contributed to improved margins.

Gland Pharma's EBITDA rose by 48% to Rs 513 crore during the quarter, compared with Rs 347.5 crore in Q4FY25. The EBITDA margin expanded to 29% from 24% a year ago.

The company's board also recommended a final dividend of Rs 20 per share for FY26, subject to shareholder approval at the upcoming AGM. The record date has been fixed as August 11.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Gland Pharma's strong performance was reflected in its consolidated revenue growth of 14.5% and an adjusted EBITDA margin of 26%. The company's Executive Chairman, Srinivas Sadu, expressed confidence in sustaining this momentum, supported by a pipeline of complex product launches and the continued ramp-up of CDMO partnerships.